REVB Revelation Biosciences Inc Total Asset Value of Company
Revelation Biosciences (REVB) operates within the biotech environment of immune system stimulation, where funding inflows depend on test results and FDA Fast Track designations accelerate time-to-market. The company is developing immune modulation methods to combat sepsis and allergies. Total assets amount to 15.98. The stock's price history confirms that the sector remains stable despite risks of supply chain disruptions and complexities regarding foreign patents.
Analytical breakdowns and data insights for company Revelation Bio (REVB)
- share price and consensus valuation forecast:
- market capitalization data:
- issuer book value statistics:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Revelation Biosciences|REVB - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Revelation Biosciences Corp|REVB - Company Aggregate Debts|Debts to Book Capitalization Revelation Biosciences Corp|REVB - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Revelation Biosciences|Interim Coverage Ratio revbiosciences.com
- net income and valuation multiples indicators:
Fundamental valuation:Revelation Biosciences
Total assets, reverse-calculated via ROA as the sum of equity and liabilities, determine the aggregate resource potential of Revelation Biosciences (REVB), which currently stands at 15.98. Analyzing the dynamics of assets (equity + liabilities) allows for an assessment of the company's financial stability during clinical trials, a period when proprietary protection of immunomodulators and FDA regulatory barriers drive the long-term business value.
Key competitors
ARGX (argenx.com) - Aggregate Company Assets|Aggregate Company Assets BioNTech|Abivax - Total Asset Value of Company|Company Total Assets ADMA|PTGX (Protagonist Corp) - Aggregate Asset Value|Company Total Assets IMVT (Immunovant, Inc.)|Company Total Assets kiniksa.com KNSA|GRFS - Aggregate Company Assets|Aggregate Asset Value ADPT (Adaptive Biotech)|Celldex (CLDX) - Aggregate Company Assets|Cumulative Company Assets Aurinia Corp|BCRX (BioCryst) - Company Total Assets|Company Total Assets veratx.com|Cumulative Company Assets DNTH (Dianthus Therapeutics, Inc.)|PHVS (Pharvaris NV) - Aggregate Asset Value|Company Total Assets ABCL (abcellera.com)|Company Total Asset Base Tourmaline (TRML)|PGEN - Aggregate Company Assets|pharming.com (PHAR) - Cumulative Company Assets|Nektar Therapeutics Inc. (NKTR) - Aggregate Company Assets|Cumulative Company Assets Upstream Bio, Inc.|Cumulative Company Assets ZBIO|Company Total Assets Immunome Bio|Aggregate Company Assets Gossamer Bio, Inc. (GOSS)|kalvista.com - Total Business Assets|Company Total Assets SEPN (Septerna)|Pieris Pharma (PVLA) - Company Assets|SVRA - Aggregate Company Assets|Aggregate Asset Value RIGL (Rigel Corp)|ANAB: Company Total Assets|Company Assets astriatx.com (ATXS)|Cumulative Company Assets ENGN|Aggregate Company Assets RAPT|Company Total Assets JBIO|ACRS - Company Assets|Aggregate Company Assets Kyverna Therapeutics KYTX|tizianalifesciences.com - Aggregate Company Assets|Cabaletta Bio - Company Total Assets|VTYX - Company Total Assets|THTX (Theratechnologies Inc) - Cumulative Company Assets|AVTX: Aggregate Business Assets|ELDN (Eledon Pharmaceuticals) - Company Total Assets|agenusbio.com (AGEN) - Company Total Asset Base|Aggregate Company Assets Climb Bio (CLYM)|ZURA - Company Assets|Aggregate Company Assets aTyr ATYR|ADAG: Total Business Assets|IMA: Cumulative Company Assets|Aggregate Asset Value STTK (Shattuck Labs, Inc.)|EQ: Company Total Assets|CNTB (Connect Biopharma Holdings Limited) - Aggregate Company Assets|IMUX (Immunic Therapeutics) - Company Total Assets|Atara Biotherapeutics Inc (ATRA) - Company Total Asset Base|Aggregate Company Assets InflaRx N.V. (IFRX)|XFOR - Company Assets|Aggregate Company Assets Adicet Bio, Inc. ACET|Company Total Asset Base Celularity Inc (CELU)|INmune Bio Corp - Company Total Assets|Barinthus Biotherapeutics Corp (BRNS) - Cumulative Company Assets|KZR: Company Total Assets|SABS - Company Total Asset Base|AKTX (Akari Therapeutics Plc) - Company Total Assets|Company Assets Enlivex Therapeutics, Ltd. ENLV|Aggregate Company Assets Q32 Bio Inc. (QTTB)|GeoVax Corp - Total Business Assets|Company Total Assets EDSA (Edesa Biotech, Inc.)|IBIO - Cumulative Company Assets|Carisma Tx - Company Total Assets|Company Assets XTL Biopharmaceuticals Ltd|boltbio.com (BOLT) - Aggregate Company Assets|HCWB - Company Total Asset Base|Aggregate Company Assets Aptevo Therapeutics, Inc.|AIM: Aggregate Asset Value|Company Total Assets ADTX|GRI - Company Assets|XORTX - Cumulative Company Assets|Vyome Therapeutics - Aggregate Company Assets|Indaptus Therapeutics - Company Total Assets|SCNI: Aggregate Company Assets|calcimedica.com (CALI) - Aggregate Company Assets|Total Asset Value of Company AFMD (Affimed N.V.)|ALLK (Allakos Inc) - Company Total Assets|HOOK: Aggregate Asset Value|Company Total Assets IGMS|Company Total Assets iteostherapeutics.com (ITOS)|Aggregate Company Assets Ocean Biomedical OCEA|Aggregate Asset Value TCBP|THRD - Aggregate Company Assets